Haemocomplettan P

Haemocomplettan P is a human fibrinogen concentrate supplied as an injectable solution for intravenous administration. The product contains purified human fibrinogen, the active ingredient, and is marketed in the European Union as a prescription‑only hemostatic agent. It is used to replace deficient fibrinogen in patients with congenital or acquired hypofibrinogenemia and to support clot formation during massive bleeding. Strength and volume are defined by the manufacturer.

Haemocomplettan P is indicated for clinical situations where fibrinogen replacement is required to achieve hemostasis.

- Congenital fibrinogen deficiency such as afibrinogenemia and hypofibrinogenemia. - Acquired hypofibrinogenemia resulting from massive hemorrhage, trauma, or major surgery. - Bleeding episodes in patients with coagulopathies where low fibrinogen contributes to uncontrolled bleeding. - Cardiopulmonary bypass or liver transplantation procedures with anticipated fibrinogen depletion. - Situations requiring rapid restoration of plasma fibrinogen levels to support clot formation.

Adverse reactions reported with Haemocomplettan P are generally related to the infusion process or to immune responses to the protein.

Common: - Mild fever or chills occurring during or shortly after infusion. - Transient hypotension or hypertension. - Nausea, vomiting, or abdominal discomfort. - Headache or dizziness.

Serious: - Allergic or anaphylactic reactions, including rash, urticaria, or bronchospasm. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. - Disseminated intravascular coagulation (rare).

When prescribing Haemocomplettan P, clinicians should evaluate patient history and monitor specific parameters to minimize risk.

- Assess baseline fibrinogen level and coagulation profile before administration. - Use caution in patients with a history of thromboembolic disease or cardiovascular disorders. - Monitor for signs of allergic reaction during and after infusion. - Adjust dose in patients with renal or hepatic impairment as recommended by the prescribing information. - Avoid concurrent use with other pro‑coagulant agents unless clinically justified. - Observe for changes in blood pressure or respiratory status during infusion. - Document infusion rate and total administered dose for safety tracking.

Haemocomplettan P may interact with other medications that affect hemostasis or immune response.

Avoid: - Concurrent administration of other fibrinogen concentrates or cryoprecipitate without clear indication. - High‑dose anticoagulants such as unfractionated heparin or direct thrombin inhibitors during infusion.

Use with caution: - Antiplatelet agents (e.g., aspirin, clopidogrel) that may alter bleeding risk. - Factor replacement therapies (e.g., factor VIII, factor IX) in patients with combined deficiencies. - Immunosuppressive drugs that could mask allergic reactions. - Vasopressors or inotropes that influence blood pressure during infusion.